Dr. Jesse Mills sits down with gastroenterologist-turned-biotech leader Dr. Josh Ofman, president of GRAIL, the company behind a groundbreaking blood test designed to detect dozens of cancers early by analyzing DNA shed by tumors. They break down how multi-cancer early detection works, who should consider testing (even before age 50), and how the technology fits into the larger—and often confusing—longevity conversation. The episode also tackles concerns about over-screening, false positives, and why waiting decades for perfect data may cost lives today.

Have a question for Dr. Mills? Send us an email at: themaleroompod@gmail.com